Drugs / MA105
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05636436 | Dec 2022 → Dec 2024 overdue | herpes zoster | MAXVAX Biotechnology Limited Liability Company | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MA105 | “0.5 mL per dose, containing low dose MA105 adjuvant.” NCT05636436 ↗ |